Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
作者信息
Hammer Andreas, Niessner Alexander, Sulzgruber Patrick
机构信息
Department of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria.
出版信息
ESC Heart Fail. 2023 Dec;10(6):3735-3738. doi: 10.1002/ehf2.14549. Epub 2023 Oct 8.
Abstract
摘要
相似文献
1
Vericiguat: a fifth cornerstone in the treatment of heart failure with reduced ejection fraction?
ESC Heart Fail. 2023 Dec;10(6):3735-3738. doi: 10.1002/ehf2.14549. Epub 2023 Oct 8.
2
[Vericiguat-new treatment option for patients with heart failure : Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA)].
Internist (Berl). 2020 Sep;61(9):989-991. doi: 10.1007/s00108-020-00828-7.
3
Effects of vericiguat in heart failure with reduced ejection fraction: do not forget sST2. Letter regarding the article 'Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction) trial'.
Eur J Heart Fail. 2020 Oct;22(10):1934-1935. doi: 10.1002/ejhf.1852. Epub 2020 Apr 30.
4
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
JACC Heart Fail. 2018 Feb;6(2):96-104. doi: 10.1016/j.jchf.2017.08.013. Epub 2017 Oct 11.
5
Vericiguat in heart failure with reduced ejection fraction: The right choice above all else? The answer may lie in time. Letter regarding the article 'Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy'.
Eur J Heart Fail. 2023 Aug;25(8):1470. doi: 10.1002/ejhf.2931. Epub 2023 Jun 21.
6
N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.
JACC Heart Fail. 2020 Nov;8(11):931-939. doi: 10.1016/j.jchf.2020.08.008. Epub 2020 Oct 7.
7
Vericiguat for the treatment of heart failure with reduced ejection fraction.
Expert Rev Cardiovasc Ther. 2023 Apr;21(4):245-257. doi: 10.1080/14779072.2023.2189101. Epub 2023 Mar 13.
8
Vericiguat in the management of heart failure with reduced ejection fraction.
Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):e65-e66. doi: 10.1093/ehjcvp/pvab022.
9
Pharmacology Focus: Vericiguat: A Novel Medication for Heart Failure with Reduced Ejection Fraction.
S D Med. 2021 Sep;74(9):440-442.
10
Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
Eur Heart J. 2017 Apr 14;38(15):1119-1127. doi: 10.1093/eurheartj/ehw593.
引用本文的文献
1
Vericiguat in patients with heart failure across the spectrum of left ventricular ejection fraction: a patient-level, pooled meta-analysis of VITALITY-HFpEF and VICTORIA.
Front Endocrinol (Lausanne). 2024 Mar 8;15:1335531. doi: 10.3389/fendo.2024.1335531. eCollection 2024.
本文引用的文献
1
Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial.
ESC Heart Fail. 2022 Dec;9(6):3791-3803. doi: 10.1002/ehf2.14050. Epub 2022 Jul 26.
2
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
3
Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial.
Eur J Heart Fail. 2021 Aug;23(8):1313-1321. doi: 10.1002/ejhf.2221. Epub 2021 Jun 3.
4
The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications.
Pharmacol Ther. 2021 Nov;227:107863. doi: 10.1016/j.pharmthera.2021.107863. Epub 2021 Apr 21.
5
Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
N Engl J Med. 2020 May 14;382(20):1883-1893. doi: 10.1056/NEJMoa1915928. Epub 2020 Mar 28.
6
Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure.
Cardiovasc Drugs Ther. 2020 Jun;34(3):401-417. doi: 10.1007/s10557-020-06959-1.
7
Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
J Am Coll Cardiol. 2019 Mar 5;73(8):935-944. doi: 10.1016/j.jacc.2018.11.049.
8
Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis.
Eur J Heart Fail. 2018 Sep;20(9):1315-1322. doi: 10.1002/ejhf.1234. Epub 2018 Jun 19.
9
Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals.
Lancet. 2018 Feb 10;391(10120):572-580. doi: 10.1016/S0140-6736(17)32520-5. Epub 2017 Nov 21.
10
Global Public Health Burden of Heart Failure.
Card Fail Rev. 2017 Apr;3(1):7-11. doi: 10.15420/cfr.2016:25:2.
Zotero 插件